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Summary
Nonalcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease,
characterized by hepatic fat accumulation and possible development of inflammation,
fibrosis, and cancer. The ketogenic diet (KD), with its drastic carbohydrate reduction,
is a now popular weight loss intervention, despite safety concerns on a possible asso-
ciation with fatty liver. However, KDs were also reported to be beneficial on hepatic
pathology, with ketone bodies recently proposed as effective modulators of inflam-
mation and fibrosis. If the beneficial impact of weight loss on NAFLD is established,
less is known on the effect of macronutrient distribution on such outcome. In a
hypocaloric regimen, the latter seems not to be crucial, whereas at higher calorie
intake, macronutrient ratio and, theoretically, ketosis, may become important. KDs
could positively impact NAFLD for their very low carbohydrate content, and whether
ketosis plays an additional role is unknown. Indeed, several mechanisms may directly
link ketosis and NAFLD improvement, and elucidating these aspects would pave the
way for new therapeutic strategies. We herein aimed at providing an accurate revi-
sion of current literature on KDs and NAFLD, focusing on clinical evidence, metabolic
pathways involved, and strict categorization of dietary interventions.
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1 | INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), defined as the spectrum
of liver diseases not associated with significant alcohol intake or
other known causes of hepatic fat accumulation, comprises “simple”
fatty liver up to severe fibrosis and inflammation, and is nowadays
the second cause of liver transplant in the United States.1 Given
the alarming increase in prevalence of this condition, research has
lately focused on several possible interventions to tame the
pandemic, with nutritional ketosis proposed as a possible treatment
option.
Ketosis is achieved when less than 50 g of carbohydrates per day
are introduced, with either restricted or unrestricted fat and calorie
intake.2 The ketogenic diet (KDs) was first introduced as an alternative
treatment for patients with refractory epilepsy, and its adapted ver-
sions later became widely popular to treat obesity thanks to their
excellent ability to induce satiety and weight loss.3 Despite their suc-
cess, some authors have raised safety concerns for KDs—especially
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those with a high fat content—for their reported effects on serum
cholesterol levels4 and liver function,5, 6 implying an influence in the
onset/worsening of hepatic steatosis.
Conversely, the beneficial effects of KDs on NAFLD have also
been reviewed, but there has been partial lack of diet categorization7,
8 and a predominant evaluation of basic science-oriented evidence.9
Because recent studies reported an interesting action of ketone bod-
ies in reducing inflammation and metabolic complications involved in
NAFLD pathogenesis,10–15 we herein aimed at providing a revision of
current literature focusing on clinical evidence relative to hepatic out-
comes, metabolic pathways possibly involved, and strict categoriza-
tion of dietary interventions, in order to aid the tailoring of dietary
interventions to the patient's needs on the one hand and direct future
research to better understand the underlying molecular mechanisms
on the other.
1.1 | What is ketosis?
Human metabolism is characterized by great flexibility, able as it is to
utilize different metabolic substrates depending of their availability to
obtain energy. Ketogenesis is a metabolic process leading to the pro-
duction of ketone bodies—acetoacetate, beta-hydroxybutyrate,
acetone—an alternative fat-derived metabolic fuel for vital organs in
states of nutrient deprivation, such as fasting, glucose deprivation,
and prolonged physical exercise.
Ketogenesis occurs in the hepatic mitochondrial matrix, where
fatty acids (FAs), released during low glucose availability states from
adipose tissue by adipokine signaling of high glucagon and epineph-
rine levels and low insulin levels, are broken down into acetyl-CoA via
β-oxidation. Under normal conditions, acetyl-CoA is further oxidized
by the citric acid cycle (TCA/Krebs cycle) and then by the mitochon-
drial electron transport chain to release energy. However, if the
amounts of acetyl-CoA generated through FA β-oxidation challenge
the processing capacity of the TCA cycle, such as in case of prolonged
fasting, glucose deprivation, and intense physical exercise, acetyl-CoA
is shifted to the biosynthesis of ketone bodies. In particular,
acetoacetate and β-hydroxybutyrate are the two ketones used by the
body for energy. Once they reach extrahepatic tissues, they are
converted back to acetyl-CoA, which goes through the TCA cycle, and
after oxidative phosphorylation, it produces 22 ATP molecules per
unit. Acetone is not converted back to acetyl-CoA, and it is either
excreted through urine or exhaled. Physiologically, ketosis takes place
in the human liver throughout the day, with a ketones production of
up to 300 g/day.16 Timing, rates, and speed of ketones production are
orchestrated by a sophisticated and well-integrated biochemical and
hormonal complex and may vary based on how intense and prolonged
the ketogenic stimulus is, sometimes leading to pathologic states such
as diabetic ketoacidosis.17
It is noteworthy to mention that prolonged fasting was ordinary
during human evolution, especially in the Paleolithic, when social
structure was based on small clusters of hunter-gatherers. The discov-
ery of agriculture in the Neolithic shifted the society dynamics
towards large communities of farmers, leading to progressively larger
abundance of food. The critical turning point came with the industrial
revolution of the 1850s, which progressively led to easy accessibility
to processed foods and to a diffusion of sedentary occupations requir-
ing less energy to be expended.18 Although evidences in this regard
are mostly deductive, it is reasonable to assume that ketosis has been
a crucial survival mechanism in humans before society became as it is
now. These considerations become interesting if we think that the
growing global widespread of obesity has followed an opposite trend
to that of prolonged fasting behaviors.
1.2 | What is a KD?
Considering the metabolic advantage of fat-derived ketones utiliza-
tion for energy purposes, in recent years, research has focused on the
nutritional induction of ketosis. A first challenge that may occur in the
study of nutritional ketosis is the definition of what is really ketogenic.
There is common agreement on the assumption that a KD consists of
a very low carbohydrate content, limited to 5–10% of total kcal daily
intake, which consists in 50—and sometime 20—grams per day,2, 19
although the specific macronutrient composition may vary. Different
types of nutritional ketosis have been defined in recent years, with or
without calorie restriction, although a clear and commonly accepted
classification does not exist yet (Table 1).
High fat KDs (HFKD), commonly simply referred as KDs, are tra-
ditionally characterized by a restriction of carbohydrates (CHO) < 50 g
per day with unrestricted intake of fat, a relative increase of protein
(0.8–1.2 g per day), and ad libitum caloric intake, although the satiety
effects tend to limit total calorie intake.20 Despite having been intro-
duced first in a neurological context, they are now the most wide-
spread weight loss-oriented KD type. Since then, moderate calorie
and fat restriction variants have been introduced, together with an
increased attention to the quality of fats.
A relatively new addition that enrichens the KD scenario is the
very low calorie KD (VLCKD), a subtype of very low calorie diet
(VLCD). This dietary pattern is far more popular in Europe than the
United States, possibly due to different eating behavior and cultural
buffering. VLCDs have extremely low daily food energy consumption
(400–800 kcal/day). Apparently, such an extreme caloric restriction, if
not accompanied by an appropriate carbohydrate intake reduction, is
not sufficient to induce a metabolic shift towards ketosis.21 The
European Food Safety Authority (EFSA) stated that VLCDs are
defined ketogenic when containing an amount of protein of
1.2–1.4 g/kg of ideal body weight (around 75 g/day), a very limited
carbohydrate content (<30–50 g/day, <5–10%), a fixed amount of fats
(20 g/day, 15–30%, mainly from olive oil), and micronutrients to fulfill
the Dietary Reference Intake.21 However, it should be acknowledged
that the threshold under which one enters a ketogenic state is subjec-
tive, and only beta-hydroxybutyrate testing would finally confirm this.
It is therefore not possible to be conclusive on the possibility that
VCLDs might cause ketosis in selected individuals, making the line
between starvation and nutritional ketosis fine.
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Often erroneously classified as KDs, low carbohydrate diets
(LCDs) do not necessarily belong to this group, with a carbohydrate
content that is typically less than 130 g/day.22, 23 LCD is not a new
dietary concept, as it was first introduced in 1863 by William Banting,
a formerly English undertaker and coffin maker with obesity, who
published “Letter on Corpulence Addressed to the Public,” in which
he described a diet for weight control giving up bread, butter, milk,
sugar, beer, and potatoes.24 In recent years, LCDs were shown to be
effective in the treatment of obesity, and apart from significantly
reducing weight, they can also effectively improve the blood lipid pro-
file and insulin resistance.23 Moreover, the American Diabetes Associ-
ation has also confirmed the effectiveness of LCDs in reducing
weight, improving blood glucose and lipids in patients with type 2 dia-
betes mellitus (T2DM).25 For the purpose of a correct pathophysiolog-
ical understanding of nutritional therapies, it appears necessary to
clearly distinguish the beneficial effects of reduction in carbohydrate
intake with and without induction of ketosis. We therefore classified
KDs as those with a CHO content below 50 g and LCDs as those with
one of 50–130 g/day. We did not include in this revision studies
involving diets defined as LCD by the authors but with a content
>130 g/day in order to limit heterogeneity.
Finally, an emerging nutritional approach capable of inducing a
certain degree of ketosis is intermittent fasting (IF), which involves a
great variety of eating patterns in which no or few calories are con-
sumed for time periods that can range from 12 h to several days. For
example, alternate-day fasting is a form of IF where individuals alter-
nate between not consuming any calories for 1 day and eating with-
out restriction the next.26 Similarly, alternate-day modified fasting is a
form of IF in which individuals alternate between consuming few calo-
ries 1 day (<25% energy needs) and eating without restriction the
next. Lately, IF has become a popular alternative to continuous calorie
restriction, and it may deliver similar benefits in terms of weight loss
and cardiometabolic health.26–30 One key mechanism responsible for
many of these beneficial effects appears to be the body's preferential
shift from glycogenolysis-derived glucose to lipolysis-derived
ketones.31
1.3 | Part of the problem …
No matter the modality through which ketosis is achieved, several
concerns have been raised regarding safety, especially long term, in
view of the described detrimental effect of the high dietary fat char-
acteristic of HFKDs possibly leading to NAFLD.32 In fact, it is well
known that in both wild type33–35 and T2DM mice models,36 KD may
promote hepatic steatosis and, in some cases, inflammation. However,
results described in rodent models consuming the KD are scarcely
translational, as the one used in animals is significantly different to
that consumed by human subjects. The first, in fact, is extremely high
in saturated fats (lard and butter), markedly low in protein content
(8.6%), and insufficient in choline, as opposed to the latter, that is
moderately high in lipids with unsaturated fat consumption usually
encouraged, it has a normal protein content, and it does not lack in
choline. This substance is indeed crucial for VLDL production, and its
lack exacerbates liver lipotoxicity, with the induction of inflammation
and fibrosis.37 Some clinical studies evaluating the effects of HFKD
on epileptic children initially suggested a potential hepatotoxic role of
these diets. Aminotransferase levels were screened and reported in
many clinical studies, which included epileptic patients treated with
HFKD.38–41 In some of them, aminotransferase levels remained
unchanged during KD treatment40, 41; in others, isolated cases of liver
enzymes rise were described,38, 39, 42, 43 although liver injury was par-
tially explained by the use of valproate.42, 43
1.4 | … or part of the solution?
Nevertheless, significant evidence suggests a hepatoprotective role
when applied to the fields of obesity and the metabolic syndrome.
NAFLD, the hepatic reflex of excess body fat, has been linked to insu-
lin resistance, increased oxidative stress, and inflammation, and it can
comprise significant fibrosis. First of all, KDs, thanks to their very low
carbohydrate content, decrease insulin levels, with subsequent reduc-
tion in lipogenesis and increase in FA oxidation rate.44 Recent evi-
dence also reports that such a drastic reduction of dietary
carbohydrates leads to a gut microbiota shift that in turn induces
folate production ameliorating lipid metabolism and limiting oxidative
stress and inflammation.45 Ketone bodies, produced in response to
carbohydrate restriction, have also been proven to induce satiety,
which leads to total calorie intake limitation and weight loss facilita-
tion, although the molecular mechanisms underlying this observed
effect have yet to be uncovered.20 Moreover, researchers' attention
has lately focused on “noncanonical” direct signaling roles of ketones,
which may play a role in the protection against and treatment of met-
abolic syndrome, including NAFLD. Intriguingly, ketones have been
proposed as direct and indirect epigenetic modifiers of key histones
that serve as dynamic regulators of chromatin architecture and gene
transcription. In particular, Shimazu et al. reported that βOHB
increased global histone acetylation with subsequent transcriptional
changes in mouse models, including genes encoding oxidative stress
TABLE 1 Classification of diets based on calorie, carbohydrate, fat daily intake and induced ketosis
kcal/day CHO/day Fat/day Ketosis
High fat ketogenic diet (HFKD) Usually unrestricted <20–50 g Unrestricted Yes
Very low calorie ketogenic diet (VLCKD) <800 kcal <20–50 g Low Yes
Very low calorie diet (VLCD) <800 kcal >20–50 g Low Usually not
Low carbohydrate diet (LCD) Variable <130 g Low No
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resistance factors, suggesting that βOHB expression may promote
oxidative stress resistance.12 Moreover, βOHB is an endogenous acti-
vator of GPR109A, abundantly expressed by many immune system
cells, including macrophages or monocytes.46 Anti-inflammatory roles
of GPR109A ligands in atherosclerosis, obesity, inflammatory bowel
disease, neurological disease, and cancer have been reported.11 βHB
has also been linked to inhibition of inflammasomes, in particular
NLRP3,15 a key signaling platform that activates proinflammatory
cytokines, in particular IL-1β and IL-18, strongly associated with obe-
sity and the pathogenesis of IR and T2DM.13 Intriguingly, growing evi-
dence supports a central role of NLRP3-induced pyroptosis in mouse
models of liver fibrosis10, 14 (Figure 1). Taken together, this body of
evidence may suggest a protective role of ketones in NAFLD patho-
genesis that possibly goes beyond simple weight loss.
2 | MATERIALS AND METHODS
Current literature was reviewed to assess the impact of different die-
tary patterns possibly leading to nutritional ketosis on NAFLD. The
research was conducted on PubMed and Embase by using the
following keywords: “ketogenic diet” or “Atkins” or “High fat low car-
bohydrate” or “very low calorie diet” or “very low calorie ketogenic
diet” or “very low energy diet” or “low energy diet” or “very low carbo-
hydrate diet” or “low carbohydrate diet” or “Intermittent fasting” and
“Non-alcoholic fatty liver disease” or “hepatic fat” or “fatty liver” or
“obesity” and related acronyms. We included all studies meeting the
following criteria: (1) observational prospective and retrospective
studies, case–control studies, cohort studies, randomized clinical trials
(RCTs); (2) reported biochemical, histological, or imaging signs relative
to outcome measures of NAFLD; (3) female only, male only, and both
genders enrolled; (4) no age limitation; (5) sufficient detail about nutri-
tional intervention reported; and (6) studies written in English.
Three independent reviewers (R. T., M. W., and R. R.) evalu-
ated the title, abstract, and keywords of selected papers, and full
articles were retrieved when deemed necessary. References of
retrieved articles were assessed for additional studies. All reports
were evaluated by two reviewers (R. T. and R. R.) for inclusion,
and a third reviewer resolved eventual disagreements (M. W.). One
reviewer (R. T.) extracted data from selected studies, which were
cross-checked by two other reviewers (M. W. and L. G.). Data
extraction included patient gender, mean age, inclusion and
F IGURE 1 Mechanisms through which a ketogenic diet (KD) might protect against nonalcoholic fatty liver disease (NAFLD). A drastic
decrease in carbohydrate intake leads to (1) decreased insulin levels with subsequent increase in fat oxidation and reduced lipogenesis and (2) a
microbiome shift with increased folate production and subsequent inflammatory and oxidative stress limitation. Ketone bodies may also induce
(1) satiety, leading to food intake limitation; (2) histone acetylation able to promote oxidative stress resistance; (3) activation of GPR109A, that is
reported to have an anti-inflammatory effect; and (4) inhibition of NLRP3, a key signaling platform that activates pro-inflammatory cytokines,
such as IL-1β and IL-18, and fibrosis inducing pyroptosis. #, decreased; ", increased; NLRP3, NLR family pyrin domain containing 3; IL, interleukin;
GPR, G protein-coupled receptor. Some illustrations adapted from Somersault18:24, CC BY-NC-SA 4.0
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exclusion criteria, sample size, study design, dietary intervention
total calorie intake and macronutrient composition, and outcomes
(biochemistry, histology, imaging).
The authors of the included studies were contacted for missing
values where required. Studies whose diet macronutrient composition
was not obtained neither through study protocol/manuscript/direct
contact with investigator were excluded.
A total of 1386 studies were identified through database search
and reference lists of retrieved articles. After removal of 1232 studies
based on title and abstract, 154 full text articles were assessed and
21 included in the present study (Figure 2).
3 | RESULTS
3.1 | High fat KDs
Commonly referred to simply as KDs, HFKD imply a carbohydrate
(CHO) content of <20–50 g/day and may be mildly hypocaloric,
normocaloric, or unrestricted, with a progressive increase in fat con-
tent. Tendler et al. recruited five patients with obesity and a histologi-
cal diagnosis of NAFLD and subjected them to a calorie unrestricted
HFKD for 6 months. Besides a general weight loss of 10.9%, improve-
ments in steatosis, necroinflammatory grade, and fibrosis were
described in four out of five patients at the end of the study. The
documented histopathological worsening of Patient 5 was hypothe-
sized to be a consequence of dietary nonadherence, as this patient
did not lose weight and had only one biochemical evidence of ketosis
during the 6-month study.47 In another prospective, 12-week study,
14 overweight male patients diagnosed with metabolic syndrome and
with ALT level > 40 UI were prescribed a Mediterranean HFKD,
unrestricted in calorie intake and high in unsaturated fats such as
omega 3 fish oil and extra virgin olive oil. At the end of the study,
there was an extremely significant improvement in body weight, ami-
notransferase level, ultrasound (US)-derived steatosis degree (com-
plete fatty liver regression was observed in 21.4% of the patients,
and an overall reduction was found in 92.86% of the patients).48 Simi-
lar results were demonstrated in a cohort of 27 patients with morbid
obesity (body mass index [BMI] of 45.2 kg/m2) in whom US-
measured hepatic lobe volume decreased by 19.8% after 4 weeks of
prebariatric HFKD at ~1250 kcal/day (CHO 4%, fat 71%, protein
25%).49 Mardinoglu et al. reported a 2-week intervention with an
HFKD (3115 kcal/day, CHO 20–30 g/day, fat 241 g/day) in
17 patients diagnosed with obesity and NAFLD. Despite the small
weight loss, a significant liver fat reduction assessed by MRS was
observed together with a concomitant decrease in hepatic de novo
lipogenesis genes45 (Table 2).
Kirk et al. conducted an RCT study on 22 subjects with obesity
on an HFKD (75% fat; CHO <60 g/day, ≈10% of daily intake;) or low
fat high CHO (LFHC) (20% fat; CHO >180 g/day, ≈65% of daily
intake) hypocaloric diet (1000 kcal daily energy deficit, based on an
estimated daily energy requirement). At 48 h, intrahepatic triglyceride
content decreased more in the HFKD than the LFHC group
(29.6 ± 4.8% vs. 8.9 ± 1.4%; p < 0.05) but was comparable after
achieving 7% weight loss in 11 weeks (HFKD vs. LFHC diet,
38.0 ± 4.5% and 44.5 ± 13.5%, respectively).59 Another RCT com-
pared an HFKD (fat 105 ± 44 g/day, ≈60%) to a hypocaloric LFHC
diet (1325 ± 180 kcal/day; CHO 165.62 ± 33 g/day, ≈50%; fat
49 ± 9 g/day, ≈35%,). Despite the slight difference in energy intake,
weight loss in both diets was similar after 2 weeks, whereas the
decrease in MRI measured hepatic triglyceride (TG) content was
greater in the HFKD group, which indeed had a higher calorie con-
tent57 (Table 3).
Altogether, these data suggest a positive effect of HFKDs on
NAFLD both in the short and medium term, independent of calorie
and fat intake. In particular, HFKDs appear to have greater and faster
impact on liver fat content compared with isocaloric high CHO diets
and to hypocaloric high CHO diets in the short term, with a possible
flattening of the discrepancies as time progresses.
3.2 | Very low calorie KDs
In a 6-week study conducted by Paoli et al., 106 patients with obesity
or overweight were sequentially placed on a 21-day VLCKD step with
significant CHO restriction (<34 g/day) and an equal duration LCD
(CHO 74 g/day). At the end of the study, no significant changes in
AST and ALT levels were detected despite weight loss and body com-
position improvement.50 Another 12-month multiphase dietetic pro-
tocol study carried out by the same group and including two VLCKD
steps resulted in significant weight loss (BMI from 35.42 ± 4.11 to
30.27 ± 3.58 kg/m2) for the majority of subjects (88.25%) followed by
successful maintenance. No significant changes in ALT, AST, or GGT
were recorded. Similar results were confirmed in a real-life setting,
where 92 patients with obesity underwent a multistep dietary inter-
vention including a VLCKD phase lasting approximately 8 weeks, andF IGURE 2 Flow chart of publications selection
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beyond the significant weight loss, no significant change in liver func-
tion was reported.54 Conversely, we conducted a 6-month study on
24 patients with obesity placed on a VLCKD with subsequent gradual
CHO reintroduction, and a significant serum AST, ALT, and triglycer-
ide decrease were detected at the end of the dietary intervention.51
In another 30-day prospective study conducted on 50 subjects with
obesity candidates to bariatric surgery that were placed on a sequen-
tial diet including a 10-day VLCKD step (CHO 15 g/day), liver
steatosis improvement and a mean 30% reduction in hepatic volume
were reported.52 Similar results were shown in 32 patients with obe-
sity placed on a VLCKD (CHO 45 g/day) for 12 weeks. At the end of
the study period, CT- and MRI-derived decrease in liver size was
28.7%, with 80% of it occurring in the first 2 weeks53 (Table 2).
Pointing towards the same direction, another study comparing
VLCKD and simple dietary counselling showed better results with
regard to US-derived decrease in liver steatosis and GGT levels reduc-
tion60 (Table 3).
The majority of the studies evaluating the effects of VLCKDs are
prospective and short term, as VLCKDs are intrinsically hard to main-
tain for longer periods of time. Moreover, given the extreme caloric
restriction, VLCKD steps only last 2–3 weeks, and most often, out-
come measures are assessed at the end of the study rather than at
the end of the most restricted first step, making overall results chal-
lenging to interpret. Paoli et al. and Bruci et al. do not report signifi-
cant biochemical improvement in liver function, conversely to what
reported by all other studies. This could be due to the relatively low
baseline BMI and AST/ALT levels of the study cohort, suggesting that
the enrolled patients might not have had NAFLD to start with.
3.3 | Low-carbohydrate non-KDs
The evaluation of the hepatic effects of low-carbohydrate non-
ketogenic (CHO content 50–130 g/day) diets, often defined as
LCDs, is complicated by the great variety of dietary composition of
this category. A 4-week hypocaloric (1520 ± 285 kcal/day) LCD
diet was reported to be effective in inducing weight loss and
decreased US-measured liver volume in patients with obesity
affected by NAFLD and candidate to bariatric surgery. A trend
improvement in fat content was also recorded55 (Table 2). An RCT
study comparing the effect of LCD and low-fat diet (LFD) on liver
fat content reported a greater decrease in MRI-measured hepatic
fat content in the LCD group.61 On the contrary, Westerbacka
et al. found that a 2-week LFD diet was more effective in reducing
proton spectroscopy-measured liver fat content compared with an
isocaloric LCD diet in 10 overweight premenopausal women, with
no change in weight being described62 (Table 3).
Evidence on hepatic outcomes in LCDs is extremely heteroge-
neous, most likely due to the great variety in dietary composition and
study duration, together with different means of assessment. How-
ever, most studies suggest that, among LCD and LFD, calorie intake is
primarily responsible in determining liver pathology improvement, and
a relatively small difference in macronutrient distribution might not be
sufficient to observe differential effects.
3.4 | Very low calorie diets
Little evidence is available on the hepatic effect of VLCDs. A pro-
spective study has shown a significant decrease in US-derived liver
volume and fat content after 6 weeks of VLCD.56 Schwenger et al.
retrospectively reported a lower prevalence of histologically con-
firmed NAFLD in a cohort of patients with obesity undergoing a
1-week prebariatric VLCD compared with what reported in litera-
ture6 (Table 2). A 12-week study conducted on Taiwanese subjects
with obesity placed on two different VLCDs (450 and 800 kcal)
were equally effective in reducing weight and degree of steatosis as
assessed by ultrasound63 (Table 3).
Altogether, available evidence suggests that such an extreme
caloric restriction is effective in improving liver conditions in subjects
with obesity, although the studies conducted so far are only short
term, and dietary interventions are incompletely described and poten-
tially leading to ketosis, which was unassessed, making the interpreta-
tion of results potentially misleading.
3.5 | Intermittent fasting
Fasting is a strong trigger to ketosis. IF regimens (IFRs) have gained
the attention of researchers and nutritionists because they have been
suggested to be a valid alternative to continuous calorie restriction.
Anton et al. classified the variety of eating patterns involving
restricted food intake or fasting in time-restricted feeding (fasting for
some hours a day), alternate days fasting (fasting every second day) or
periodic fasting (fasting for some days every week), reviewing how
the different regimens induce the switch to ketogenic metabolism.31
The large majority of studies evaluating the effects of IFRs only
focused on body composition and glucometabolic outcomes both
short and long term, showing equal ability to induce weight loss and
decrease insulin resistance in patients with obesity compared with
simple calorie restriction.31 A study conducted by Browning et al.
investigating the MRI-derived intrahepatic triglyceride content modifi-
cation of 18 healthy subjects upon a 48-hr fast showed a sexually
dimorphic response of liver lipid accumulation, where men experi-
enced a modest but significant increase (p = 0.043), as opposed to
women who trended towards decrease (p = 0.092).57 Wilhelmi de
Toledo et al. evaluated 1422 subjects participating in a fasting pro-
gram consisting of fasting periods of 4–21 days according to the
Buchinger guidelines over 12 months. Daily caloric intake was
200–250 kcal during fasting periods, whose lengths were 5, 10, 15, or
20 ± 2 days. Besides overall significant reductions in weight, abdomi-
nal circumference, and blood pressure (p < 0.001), biochemical liver
function indices showed a significant AST and ALT rise throughout
the fast without difference between groups, although the values at
baseline and at the end remained within normal ranges. Conversely, a
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more significant decrease of GGT and Alkaline phosphatase were
observed in the longer fasting groups58 (Table 2).
Evidence on the hepatic effects of IFRs are too few and contro-
versial to draw definitive conclusions. However, recent evidence sug-
gests that IFRs leads to ketosis and metabolic improvement likely to
cause amelioration of NAFLD.64, 65 Targeted clinical studies are there-
fore needed to confirm whether the equal ability versus simple caloric
restriction observed regarding body composition and glucometabolic
outcomes is also true regarding liver function and pathology.
4 | CONCLUSION
Whether it is acknowledged that weight loss is associated with ame-
lioration of NAFLD,66, 67 less is known relative to the effect of macro-
nutrient distribution on such outcome.68 Virtually, all reviewed
studies assessing liver fat content report positive results after VLCDs,
VLCKDs, and HFKDs, with inconclusive results after LCDs diets and
IFRs. It should be acknowledged that the high heterogeneity of the
reports precluded a meta-analytic approach. Moreover, many of the
cited studies involved less than 50 individuals, limiting the generaliza-
tion of results to a wider NAFLD population. Altogether, these data
suggest that both caloric restriction and macronutrient distribution
play a role that might be either additive or synergistic. The common
belief that increasing dietary fat intake invariably leads to fatty liver
and prevents fat mass loss has been recently proven wrong by an ele-
gant experiment, showing that a normocaloric HFKD inhibits de novo
lipogenesis and induces FA oxidation, leading to weight loss and
reduced hepatic fat content.69 On the contrary, a hypercaloric bal-
anced diet decreases intrahepatic FA oxidation and increases de novo
lipogenesis primarily from carbohydrate, and not lipid substrates, lead-
ing to NAFLD development.70 At very low caloric intake, macronutri-
ent distribution might not be crucial in obtaining liver pathology
improvement that seems to be driven by weight loss itself, whereas at
higher caloric contents, macronutrient ratio and, possibly, ketosis,
seem to become more important, and the positive effect might be
independent of weight modifications and calorie intake. Carbohydrate
restriction, with its well-established role in modulating insulin levels,
and the newly proposed pathway involving the microbiome shift with
increased folate production, surely plays a primary role in the reported
effectiveness of KDs towards NAFLD. Apart from being the metabolic
consequence of FA oxidation leading to liver fat reduction, ketosis
may itself be involved in NAFLD pathogenesis through several mecha-
nisms previously described (Figure 1) beyond carbohydrate restriction.
Interestingly, ketone esters have been administered to athletes,
reducing glycolysis and increasing muscle fat oxidation in the absence
of a carbohydrate-restricted diet,71 but no evidence is available to
date regarding subjects with NAFLD. This finding suggests that keto-
sis might exert beneficial effects independent of dietary composition
and therefore warrants studies aiming at identifying the specific role
played by ketone bodies in NAFLD pathophysiology, possibly paving
the way for new therapeutic targets and strategies.
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